Biophore india pharmaceuticals - Latest News Update, Information, Photos & Videos on Biophore india pharmaceuticals at Lokmat Times

Hyderabad, June 11 Hyderabad-based Biophore India Pharmaceuticals announced on Friday that it has applied for DCGI emergency use approval of Aviptadil Inhalation for marketing in India for the treatment of moderate to severe cases of Covid-19.Biophore has successfully developed Aviptadil and is backward integrated with in-house API (Active Pharmaceutical Ingredient).The company will be commencing commercial production immediately after the approval is received from Drugs Controller General of India (DCGI).Aviptadil is a synthetic form of Vasoactive Intestinal Peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection.These observations are based on results of multiple trials of Aviptadil against Covid-19 globally in patients with respiratory failure and the same have been submitted to DCGI for their review, it said."Biophore has developed this highly complex peptide in a very short period of time, primarily due to the extensive focus of the company in prioritizing Covid related products over the last one year.Aviptadil is a very promising treatment option for Covid, especially in severe hospitalized cases where trials have shown a high recovery percentage and we hope to be able to quickly make it available through this approval," said Biophore CEO Jagadeesh Babu Rangisetty.Biophore has been actively involved in developing products against Covid-19 and scaling up manufacturing to meet the requirements. The company was one of the first few manufacturers to have received approval for an anti-viral agent, Favipiravir, in India during the first wave and is also the only Indian manufacturer to be producing multi tonnage volumes of Sulfobutyl Ether beta Cyclodextrin (SBECD), which is a key excipient in the manufacturing of Remdesivir injections.Apart from these, Biophore has invested significantly into the research and development of other anti-Covid products over the last one year"While we are optimistic that the pandemic will end soon, we have to be prepared for the exigencies. We need to keep evaluating and adding newer products against this virus to ensure better preparedness by having more options for the treating physic and thus avoiding shortages. Our aim is also to make the cost of treatment affordable, especially for hospitalized patients," said Jagadeesh Babu.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Lok Sabha Election 2024

Heatwave In India

Mumbai Water Cut

Maharashtra Lok Sabha Election

IPL 2024

Salman Khan

Biophore India PharmaceuticalsFOLLOW

Biophore india pharmaceuticals, Latest News

Business :Biophore and its subsidiary, Zenara Pharma, receive the first approval for Cannabidiol in India

100% Made-in-India including the active ingredient Manufactured in US FDA and EU-approved facility in India Indicated for the treatment of neuro disorders Delhi NCR (India), May ... ...

Health :Biphore, Zenara get CDSCO approval for neuro disorder drug

Hyderabad, May 15 Hyderabad-based Biophore India Pharmaceuticals has announced that it has received approval from he Central Drugs ... ...

Health :Biophore receives sub-license to manufacture Molnupiravir

Hyderabad, Jan 20 Biophore India Pharmaceuticals on Thursday announced that it has received license from Medicines Patent Pool ... ...

Health :Hyderabad's Biophore to manufacture ingredients of Pfizer's Covid drug

Hyderabad, Jan 19 Biophore India Pharmaceuticals on Wednesday announced that it developed and started manufacturing the key intermediates ... ...

Health :Biophore seeks DCGI approval for Aviptadil for Covid treatment

Hyderabad, June 11 Hyderabad-based Biophore India Pharmaceuticals announced on Friday that it has applied for DCGI emergency use ... ...